Tag Archive for: retinal vascular disease

Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer

/in

Collaboration to advance development of innovative oral small molecule therapeutics for retinal disorders Milan, Italy and Copenhagen, Denmark, 25 July 2023 – Golgi Neurosciences S.r.l., the biotech incubator dedicated to the development of new treatments for devastating diseases, and Breye Therapeutics ApS, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases, today announces […]

Read more

Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseases

/in

Industry expert Ulrik Mouritzen M.D. appointed Chief Executive Officer Funding to advance lead asset to phase 1b clinical trial and further build pipeline COPENHAGEN, Denmark, Nov. 10, 2022 /PRNewswire/ — Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces it has emerged from stealth after closing a seed financing of EUR […]

Read more